Matches in SemOpenAlex for { <https://semopenalex.org/work/W3088370354> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W3088370354 endingPage "S752" @default.
- W3088370354 startingPage "S751" @default.
- W3088370354 abstract "Preclinical data suggest that BRAF inhibition provides a more favorable immune microenvironment for subsequent response to immunotherapy. We aimed to evaluate the efficacy and safety of combining vemurafenib (BRAF inhibitor) with a programmed death 1 (PD-1) inhibitor in patients with BRAFV600-mutant melanoma in China. Advanced BRAFV600-mutant melanoma patients treated with vemurafenib and anti-PD-1 antibody at Sun-Yat Sen University Cancer Center between June 2017 and May 2019 were retrospectively analyzed. Vemurafenib was administered with a 4–6-weeks run-in period followed by PD-1 blockade (pembrolizumab or toripalimab) combined with vemurafenib until disease progression or unacceptable toxicity. Response was assessed by the Response Evaluation Criteria in Solid Tumors version 1.1. In total, 39 patients were included. All the patients had tumor shrinkage. The objective response rate was 64.1% (95% CI, 48.7–79.4) and the complete response was observed in 8 (20.5%; 95% CI, 7.7–33.3) patients. The median progression-free survival (PFS) was 13.2 months (95% CI: 8.2–18.2). The median duration of response (DOR), and overall survival (OS) were not reached after a median follow-up of 12.1 months. The response was ongoing in 16 (41%) patients. The estimated 1-year survival rate was 86.7%. During the combination therapy, treatment-related adverse events (TRAEs) of any grade occurred in 36 (92.3%) patients. Eleven patients (28.2%) experienced grade 3/4 TRAEs, 10 presented with rash and 1 with elevated transaminase. TRAEs led to discontinuation of ≥1 study drug in seven (17.9%) patients. Programmed death ligand 1 expression on the tumor cell and tumor mutation burden at baseline did not correlate with response rate and survival time.Table: 1114PCharacteristicNo. of patients (%), n=39Age, years51 (24–77)Male26 (66.7)ECOG022 (56.7)117 (43.6)Clinical subtype of primary tumorAcral2 (5.1)CSD11 (28.2)Non-CSD19 (48.7)Unknown7 (17.9)Brain metastasesYes6 (15.4)No33 (84.6)Liver metastasesYes11 (28.2)No28 (71.8)Metastatic organs>217 (43.6)≤222 (56.4)LDH≤UNL30 (76.9)＞UNL9 (23.1)Prior systemic therapyNo29 (74.4)Yes10 (25.6) Open table in a new tab Vemurafenib combined with anti-PD-1 antibody had promising clinical activity and manageable safety. Toxicity, especially rash, is more common for this combination than for either agent alone." @default.
- W3088370354 created "2020-10-01" @default.
- W3088370354 creator A5015826494 @default.
- W3088370354 creator A5017347666 @default.
- W3088370354 creator A5030976623 @default.
- W3088370354 creator A5031810127 @default.
- W3088370354 creator A5046500307 @default.
- W3088370354 date "2020-09-01" @default.
- W3088370354 modified "2023-10-18" @default.
- W3088370354 title "1114P A real-world study of vemurafenib plus anti-PD-1 antibody in Chinese patients with advanced BRAF V600-mutant melanoma" @default.
- W3088370354 doi "https://doi.org/10.1016/j.annonc.2020.08.1237" @default.
- W3088370354 hasPublicationYear "2020" @default.
- W3088370354 type Work @default.
- W3088370354 sameAs 3088370354 @default.
- W3088370354 citedByCount "1" @default.
- W3088370354 countsByYear W30883703542020 @default.
- W3088370354 crossrefType "journal-article" @default.
- W3088370354 hasAuthorship W3088370354A5015826494 @default.
- W3088370354 hasAuthorship W3088370354A5017347666 @default.
- W3088370354 hasAuthorship W3088370354A5030976623 @default.
- W3088370354 hasAuthorship W3088370354A5031810127 @default.
- W3088370354 hasAuthorship W3088370354A5046500307 @default.
- W3088370354 hasBestOaLocation W30883703541 @default.
- W3088370354 hasConcept C121608353 @default.
- W3088370354 hasConcept C126322002 @default.
- W3088370354 hasConcept C143998085 @default.
- W3088370354 hasConcept C197934379 @default.
- W3088370354 hasConcept C2776131300 @default.
- W3088370354 hasConcept C2776694085 @default.
- W3088370354 hasConcept C2777658100 @default.
- W3088370354 hasConcept C2777701055 @default.
- W3088370354 hasConcept C2778570526 @default.
- W3088370354 hasConcept C2778715236 @default.
- W3088370354 hasConcept C2778830669 @default.
- W3088370354 hasConcept C2780057760 @default.
- W3088370354 hasConcept C2780739268 @default.
- W3088370354 hasConcept C2781433595 @default.
- W3088370354 hasConcept C2994587330 @default.
- W3088370354 hasConcept C502942594 @default.
- W3088370354 hasConcept C71924100 @default.
- W3088370354 hasConcept C90924648 @default.
- W3088370354 hasConceptScore W3088370354C121608353 @default.
- W3088370354 hasConceptScore W3088370354C126322002 @default.
- W3088370354 hasConceptScore W3088370354C143998085 @default.
- W3088370354 hasConceptScore W3088370354C197934379 @default.
- W3088370354 hasConceptScore W3088370354C2776131300 @default.
- W3088370354 hasConceptScore W3088370354C2776694085 @default.
- W3088370354 hasConceptScore W3088370354C2777658100 @default.
- W3088370354 hasConceptScore W3088370354C2777701055 @default.
- W3088370354 hasConceptScore W3088370354C2778570526 @default.
- W3088370354 hasConceptScore W3088370354C2778715236 @default.
- W3088370354 hasConceptScore W3088370354C2778830669 @default.
- W3088370354 hasConceptScore W3088370354C2780057760 @default.
- W3088370354 hasConceptScore W3088370354C2780739268 @default.
- W3088370354 hasConceptScore W3088370354C2781433595 @default.
- W3088370354 hasConceptScore W3088370354C2994587330 @default.
- W3088370354 hasConceptScore W3088370354C502942594 @default.
- W3088370354 hasConceptScore W3088370354C71924100 @default.
- W3088370354 hasConceptScore W3088370354C90924648 @default.
- W3088370354 hasLocation W30883703541 @default.
- W3088370354 hasOpenAccess W3088370354 @default.
- W3088370354 hasPrimaryLocation W30883703541 @default.
- W3088370354 hasRelatedWork W1612479149 @default.
- W3088370354 hasRelatedWork W1915698186 @default.
- W3088370354 hasRelatedWork W2269603252 @default.
- W3088370354 hasRelatedWork W2989785091 @default.
- W3088370354 hasRelatedWork W2994436620 @default.
- W3088370354 hasRelatedWork W3088370354 @default.
- W3088370354 hasRelatedWork W4206663608 @default.
- W3088370354 hasRelatedWork W4283513241 @default.
- W3088370354 hasRelatedWork W4308181630 @default.
- W3088370354 hasRelatedWork W4361298402 @default.
- W3088370354 hasVolume "31" @default.
- W3088370354 isParatext "false" @default.
- W3088370354 isRetracted "false" @default.
- W3088370354 magId "3088370354" @default.
- W3088370354 workType "article" @default.